Stock Events

Stock Events

Search...

Evolus

$4.17

0

+$0+0% Wednesday 07:54

Statistics

Day High

4.17

Day Low

4.17

52W High

-

52W Low

-

Volume

264

Avg. Volume

-

Mkt Cap

270.3M

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

12MayExpected

Q3 2025

Q4 2025

Next

-0.16

-0.09

-0.02

0.05

Expected EPS

-0.110317

Actual EPS

N/A

Financials

-18.94%Profit Margin

Unprofitable

2019

2020

2021

2022

2023

2024

532.55MRevenue

-100.84MNet Income

Analyst Ratings

$15.50Average Price Target

The highest estimate is 19.00.
From 5 ratings within the last 6 months. This is not an investment recommendation.

Buy

80%

Hold

20%

Sell

0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow EOLS.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Merck & Co., through its acquisition of companies and products, competes in the aesthetics and dermatology space, potentially overlapping with Evolus's market.

GlaxoSmithKline, a large pharmaceutical company, has a diverse portfolio that includes products competing in the aesthetics space.

Pfizer, with its broad range of healthcare products, competes in various segments, including those that overlap with Evolus's interests.

AbbVie, after acquiring Allergan, directly competes with Evolus in the cosmetic injectable market, particularly with its Botox product.

State Street Global Allocation

Galderma, a company specializing in dermatological treatments, offers a range of products that compete in the same space as Evolus's offerings.

Revolve, while primarily known for its fashion retail, has ventured into beauty and skincare products that could indirectly compete with Evolus.

Johnson & Johnson

Johnson & Johnson, through its wide range of healthcare products, has interests in the dermatology and aesthetics market, competing with Evolus.

Teva- Pharmaceutical Industries

Teva Pharmaceutical Industries, with its generic and specialty medicines, competes in the broader pharmaceutical market, including areas relevant to Evolus.

Novartis, a global healthcare company, has a diverse portfolio that includes dermatology and aesthetics, competing with Evolus in certain markets.

About

Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Show more...

CEO

ISIN

US30052C1071

Listings

0 Comments

Share your thoughts

FAQ

What is Evolus stock price today?▼

The current price of EOLS.BOATS is $4.17 USD — it has increased by +0% in the past 24 hours. Watch Evolus stock price performance more closely on the chart.

What is Evolus stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Evolus stocks are traded under the ticker EOLS.BOATS.

What is Evolus market cap?▼

Today Evolus has the market capitalization of 270.3M

When is the next Evolus earnings date?▼

Evolus is going to release the next earnings report on May 12, 2026.

What were Evolus earnings last quarter?▼

EOLS.BOATS earnings for the last quarter are 0.04 USD per share, whereas the estimation was 0.05 USD resulting in a -2.09% surprise. The estimated earnings for the next quarter are N/A USD per share.

What is Evolus revenue for the last year?▼

Evolus revenue for the last year amounts to 532.55M USD.

What is Evolus net income for the last year?▼

EOLS.BOATS net income for the last year is -100.84M USD.

When did Evolus complete a stock split?▼

Evolus has not had any recent stock splits.